Torvutatug samrotecan not checked

AstraZeneca · AZD5335 · AZ14170132

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
5 active
5 in total · 3 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-tug: unmodified immunoglobulins WHO name stem
How it’s given
“FRa targeting antibody drug conjugate Topoisomerase I inhibitor”In the company’s words, NCT07816666 on ClinicalTrials.gov
Tested for
Epithelial Ovarian Cancer (2 trials), Ovarian Cancer (2 trials), Platinum-sensitive Relapsed Epithelial Ovarian Cancer, Platinum-sensitive Relapsed Fallopian Tube Cancer, Platinum-sensitive Relapsed Primary Peritoneal Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma and 2 more
Main trialPhase 3
“The purpose of this study is to measure the efficacy and safety of torvutatug samrotecan (torvu-sam) with or without bevacizumab compared to standard of care (SoC) as maintenance treatment in participants with platinum-sensitive relapsed ovarian cancer (PSR OC)”In the company’s words, NCT07816666 on ClinicalTrials.gov
Other names
AZD5335 · AZ14170132 · Torvu-sam

Other drugs for Epithelial Ovarian Cancer

All 35 drugs for Epithelial Ovarian Cancer

Coming up5

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials5

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 29 Sep 2028 Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer
Phase 3Recruiting 17 Nov 2028 AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Phase 3Recruiting 28 Jun 2030 Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Phase 1/2Recruiting 4 Aug 2028 Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Phase 1Recruiting 15 Oct 2027 Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Torvutatug samrotecan

Following is part of Solo: you see every change to Torvutatug samrotecan the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in